Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBF-680 in mild-to-moderate persistent atopic asthma
2017-003663-35Phase 2Completed
- Sponsor
- Palobiofarma
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing PBF-680 with Placebo (2 arms). Primary endpoint: Improvement in trough FEV1. Started Jan 2018; status: completed.
02
Drugs
PBF-680
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-003663-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003663-35.